Growth & profitability
- Revenue has grown 104.8% per year over the past 5 years.
KNSA Financials Kiniksa Pharmaceuticals International, Plc
9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $678M | $59M | 88.5% | 11.4% | $136M | — | $166M |
| 2024 | $423M | -$43M | 85.6% | -10.8% | $25M | — | $184M |
| 2023 | $270M | $14M | 87.6% | -9.3% | $13M | — | $108M |
| 2022 | $220M | $183M | 89.6% | 4.4% | $6M | — | $123M |
| 2021 | $39M | -$158M | 76.4% | -406.4% | -$127M | — | $122M |
| 2020 | — | -$161M | — | — | -$137M | — | $114M |
| 2019 | — | -$162M | — | — | -$162M | — | $47M |
| 2018 | — | -$103M | — | — | -$86M | — | $72M |
| 2017 | — | -$65M | — | — | -$50M | — | $46M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $214M | $23M | 90.3% | 13.7% | $50M | — | $190M |
| Dec '25 | $202M | $14M | 89.6% | 9.8% | $53M | — | $166M |
| Sep '25 | $181M | $18M | 88.8% | 13.3% | $33M | — | $175M |
| Jun '25 | $157M | $18M | 88.1% | 12.9% | $28M | — | $192M |
| Mar '25 | $138M | $9M | 87.0% | 9.6% | $22M | — | $157M |
| Dec '24 | $123M | -$9M | 85.4% | -15.7% | $19M | — | $184M |
| Sep '24 | $112M | -$13M | 82.1% | -8.6% | -$2M | — | $97M |
| Jun '24 | $109M | -$4M | 88.7% | -0.1% | $5M | — | $99M |
| Mar '24 | $80M | -$18M | 86.7% | -20.7% | $4M | — | $141M |
| Dec '23 | $83M | $25M | 88.5% | 0.1% | $4M | — | $108M |
| Sep '23 | $67M | -$14M | 86.4% | -16.3% | $17M | — | $118M |
| Jun '23 | $71M | $15M | 89.2% | -4.4% | -$4M | — | $113M |
| Mar '23 | $48M | -$12M | 85.4% | -23.2% | -$4M | — | $81M |
| Dec '22 | $62M | $4M | 0.0% | 9.8% | -$12M | — | $123M |
| Sep '22 | $99M | $224M | 93.0% | 46.8% | $62M | — | $176M |
| Jun '22 | $27M | -$20M | 81.4% | -71.8% | — | — | $94M |
| Mar '22 | $32M | -$25M | 0.0% | -72.4% | — | — | $63M |
| Dec '21 | $19M | -$36M | 79.4% | -192.8% | -$19M | — | $122M |
| Sep '21 | $12M | -$31M | 77.1% | -253.6% | -$29M | — | $190M |
| Jun '21 | $8M | -$42M | 68.0% | -526.4% | -$39M | — | $168M |
Valuation over time
How the market has priced KNSA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 4.5× (Mar '23) to 73.9× (Jun '26).
- The price-to-sales ratio has risen from 3.7× (Mar '23) to 6.4× (Jun '26).
P/E
P/S
Frequently asked questions
Is KNSA growing its revenue and profit?
Over the past 5 years, Kiniksa Pharmaceuticals International, Plc's revenue has grown 104.8% per year. These are computed facts, not advice.
How much debt does KNSA have?
As of FY2025, Kiniksa Pharmaceuticals International, Plc reported — of total debt against $166M of cash.
What is KNSA's profit margin?
In FY2025, gross margin was 88.5%, operating margin 11.4%, and net margin 8.7%.
What is KNSA's P/E ratio?
As of Jun '26, Kiniksa Pharmaceuticals International, Plc traded at a price-to-earnings ratio of about 73.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.